Boltz raises $110M Series A for AI biomolecular design, partners with 6 top-20 pharma giants

GabriCorso · x · 2026-11-18

Boltz has raised a $110M Series A led by Bessemer VP, following 50x growth in molecular token usage since June. Its partners include Pfizer, GSK, Takeda and BMS — 6 of the world's 20 largest pharma companies.

The team's long-term goal: a scientist goes from therapeutic hypothesis to human-ready molecule entirely on a computer. BoltzMol-1 and BoltzProt-1 (released in June) took a key step toward reliable small-molecule hit discovery and protein binder design for hard targets; next-gen models already show substantial quality gains, and the funding goes into compute, data and team.

Related event: Boltz raises $110M Series A for AI biomolecular design, partners with 6 top-20 pharma giants(3 posts)→

Original post →

More from Venture

Venture channel →